Literature DB >> 1337067

The molecular basis of quinolone action.

A Maxwell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1337067     DOI： 10.1093/jac/30.4.409

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  40 in total

1.  In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron.

Authors:  B Pradines; C Rogier; T Fusai; J Mosnier; W Daries; E Barret; D Parzy
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  The alpha4 residues of human DNA topoisomerase IIalpha function in enzymatic activity and anticancer drug sensitivity.

Authors:  Namiko Suda; Yasutomo Ito; Tsuneo Imai; Toyone Kikumori; Akihiko Kikuchi; Yukihiro Nishiyama; Shonen Yoshida; Motoshi Suzuki
Journal:  Nucleic Acids Res       Date:  2004-03-16       Impact factor: 16.971

3.  Replicative helicases can translocate through abasic site-induced covalent topoisomerase IV-DNA complexes.

Authors:  M E Shea; H Hiasa
Journal:  Nucleic Acids Res       Date:  2001-02-01       Impact factor: 16.971

4.  Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in Quinolone-resistant Shigella dysenteriae serotype 1 clinical isolates from Kolkata, India.

Authors:  Shanta Dutta; Yoshiaki Kawamura; Takayuki Ezaki; Gopinath Balakrish Nair; Ken-Ichiro Iida; Shin-Ichi Yoshida
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  DNA gyrase can cleave short DNA fragments in the presence of quinolone drugs.

Authors:  M E Cove; A P Tingey; A Maxwell
Journal:  Nucleic Acids Res       Date:  1997-07-15       Impact factor: 16.971

6.  Mode of action of GR122222X, a novel inhibitor of bacterial DNA gyrase.

Authors:  M Oram; B Dosanjh; N A Gormley; C V Smith; L M Fisher; A Maxwell; K Duncan
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

7.  Conversion of DNA gyrase into a conventional type II topoisomerase.

Authors:  S C Kampranis; A Maxwell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

8.  RNA polymerase (rpoB) mutants selected for increased resistance to gyrase inhibitors in Salmonella typhimurium.

Authors:  A B Blanc-Potard; E Gari; F Spirito; N Figueroa-Bossi; L Bossi
Journal:  Mol Gen Genet       Date:  1995-06-25

9.  A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential.

Authors:  A H Corbett; P Guerry; P Pflieger; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

Review 10.  Quinolone mode of action--new aspects.

Authors:  D C Hooper
Journal:  Drugs       Date:  1993       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.